The discovery and subsequent introduction of dantrolene in 1979 was a major breakthrough in the treatment of malignant hyperthermia (MH) that is responsible for saving hundreds, if not thousands, of ...

Malignant hyperthermia (MH) is a life‐threatening pharmacogenetic disorder of skeletal muscle characterised by a hypermetabolic response to certain anaesthetic agents. Research in this field has ...

A team of researchers led by Osaka University finds that mutant variants of the calcium channel protein RyR1 are hypersensitive to heat, which creates a positive feedback loop of calcium release and ...

In their presentation of a case of rhabdomyolysis possibly associated with mRNA SARS-CoV-2 vaccination, Salter and colleagues1 are to be commended for elucidating the relevant differential diagnosis, ...

“Uncle Joe woke up from minor surgery packed in ice.” That’s more than interesting family gossip. It’s an ominous clue that Joe’s relatives are at risk for a rare, inherited condition that can make ...

The Ambulatory Surgery Foundation and Malignant Hyperthermia Association of the United States have announced the joint release of guidelines to help ASCs develop plans for properly transferring a ...

hyperthermia (MH), along with the appropriate supportive measures. MH is an inherited and potentially fatal disorder triggered by certain anesthesia agents in genetically susceptible individuals. FDA ...

image: Schematic representation of the mechanism leading to prolonged bleeding time due to RYR1 mutations. In normal conditions (left panel), early vasospasm occurring immediately after injury reduces ...